Showing 5191-5200 of 8729 results for "".
- Study Validates Thermal Imaging, ALT-70 Model for Distinguishing Cellulitis from Pseudocellulitishttps://practicaldermatology.com/news/study-validates-thermal-imaging-alt-70-model-distinguishing-cellulitis-pseudocellulitis/2462541/A new diagnostic validation study in JAMA Dermatology has shed light on the potential of surface thermal imaging and the ALT-70 (asymmetry, leukocytosis, tachycardia, and age ≥70 years) prediction model in differentiating cellulitis from pseudocellulitis. "Cellulitis is misdiagno
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- Integrated Dermatology Appoints Tushar Ramani, MD, as CEOhttps://practicaldermatology.com/news/integrated-dermatology-appoints-tushar-ramani-md-ceo/2462493/Integrated Dermatology has announced the appointment of Tushar Ramani, MD, as the company's new chief executive officer (CEO). Dr. Ramani will be replacing Jeff Queen, who after two decades as CEO and executive chairman, is transitioning to the role of co-executive chairman of the Board alongside
- Updated Coding Curbs Complex Repair Billing by Mohs Surgeonshttps://practicaldermatology.com/news/updated-coding-curbs-complex-repair-billing-mohs-surgeons/2462489/Complex repairs billed by Mohs surgeons decreased significantly from 2019 to 2021 in the wake of new coding guidelines, according to a national Medicare analysis. Publishing in Dermatologic Surgery, Christian Gronbeck, MD, of the University of Connecticut, Farmington, and colleag
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- Review: Lack of Specificity Seen in Outcome Measurement Instruments Used for AE Reporting in Cancer Trialshttps://practicaldermatology.com/news/outcome-measurement-instruments-used-to-evaluate-dermatologic-adverse-events-in-cancer-trials/2462443/Some common measurement instruments of patient-reported outcomes in skin cancer trials lack specificity and rigorous validation, according to a new systematic review. "Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated
- Ted Danson Partners with Bristol Myers Squibb for Plaque Psoriasis Campaignhttps://practicaldermatology.com/news/ted-danson-partners-with-bristol-myers-squibb-for-plaque-psoriasis-campaign/2462442/Bristol Myers Squibb has partnered with award-winning actor Ted Danson, who lives with plaque psoriasis, for a new campaign called “
- Study Highlights Orofacial Anomalies in Kindler Epidermolysis Bullosahttps://practicaldermatology.com/news/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2462441/A new study in JAMA Dermatology suggests that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa (KEB). "Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic varia
- Mediterranean Diet Adherence Not a Factor in Diagnosis or Severity of Acne: Studyhttps://practicaldermatology.com/news/mediterranian-diet-not-linked-with-acne-development-study/2462437/Results from a new analysis in the Journal of Health, Population, and Nutrition failed to show a link between adherence to a Mediterranean diet and an impact on acne severity or diagnosis. "Western diets, characterized by a high glycemic index and dairy content, can be risk fact
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop